Study: A lipid emulsion containing 10 percent mediumchain triglycerides (MCT) and 10 percent long-chain triglycerides (LCT) was infused at a rate of 1 ml/kg/h (3.3 mg/kg/min) for 2 h, in 12 patients (2 males, 10 females; mean age, 54±3 (SEM) years; range, 34 to 67 years) 24 h after open-heart surgery (mitral valve replacement). Methods: Hemodynamic factors (pulmonary and radial artery indwelling catheters), oxygen and carbon dioxide partial pressures, oxygen saturation, oxygen delivery and consumption, and intrapulmonary shunt fraction were obtained before, during, and after lipid infusion (for 2 h), at 30-s intervals, along with some metabolic indexes (triglycerides, free fatty acids, glucose, insulin, lactate, acetoacetate). Results: No statistically significant changes in heart rate, cardiac index, systemic and pulmonary pressures and resistances, central venous and pulmonary capillary pressures, or arterial oxygen partial pressure were observed during infusion. Arterial carbon dioxide partial pressure values were constantly reduced throughout and after the end of lipid infusion, as compared with baseline values, while oxygen consumption was increased significantly without any change in oxygen delivery. No factor in determining cardiopulmonary effects of IVFE.1920 Long-chain polyunsaturated fatty acids serve, in fact, as precursors of prostaglandins and thromboxanes. These eicosanoids are known to exert composite effects on vascular tone-in particular on the pulmonary vascular bed-with possible consequences on pulmonary gas exchange as well. 1920 The search for alternative lipid sources has led to the formulation of new lipid emulsions, characterized by the partial replacement of LCT with medium-chain triglycerides (MCT). The latter are semisynthetic triacylglycerols obtained from hydrolysis of coconut oil and fractionation into free fatty acids (FFA) with 6 and 12 carbon atoms (mainly C8 and C10 fatty acids). Because MCT do not interfere with eicosanoid synthesis and availability, their presence as components of IVFE could be associated with reduced or no adverse cardiopulmonary effects, even in patients with respiratory or cardiac illness, or both. Moreover, in the critically ill patient, the use of MCT could provide many metabolic benefits, such as lesser carnitine requirements for mitochondrial entry, rapid metabolization to readily available fuels (acetylCoA and ketone bodies), no needs for storage in adipose tissue and no deposition in the reticuloendothelial system.2'
A physical mixture of MCT and LCT is currently available for clinical use, and the present study was thus designed to evaluate its cardiopulmonary and metabolic effects. To this purpose, during the administration of the MCT/LCT IVFE in the early postoperative period following open-heart surgery for mitral valve disease, clinical, respiratory, hemodynamic, and metabolic monitoring was performed in a group of patients in the heart surgery ICU.
PATIENTS AND METHODS

Patients
Subjects scheduled for elective cardiac surgery for mitral valve disease at the Heart Surgery Division were considered eligible for the study. Patients were evaluated 24 h after the end of the operative procedures in the heart surgery ICU: they were excluded from the study if a stable postoperative course was not demonstrated on the basis of respiratory and hemodynamic monitoring and/or they were not extubated. Moreover, the presence of any of the following conditions (before or after surgery) was considered an exclusion criterion: preoperative chronic renal failure, diabetes and dyslipidemia, acute perioperative myocardial infarction, postoperative cardiac index less than 2.2 L/min, acute renal failure, fever (>380C), and nonsteroidal antiinflammatory drug administration. Twelve patients (functional class Il-III New York Heart Association classification) were selected. There were ten females and two males, with a mean age of 54 years (3.2 SEM; range, 43 to 67 years). Explanation as to the nature, purpose, and potential risks of the study was given to all patients; written informed consent was obtained from each participant for all procedures before surgery. The study was conducted according to the principles embodied in the Declaration of Helsinki.
Study Protocol
Routine hemodynamic and respiratory monitoring was performed according to institutional protocols: on the day of the operative procedure, in the operating room, an indwelling catheter was inserted into the radial artery for monitoring and sampling; after anesthesia induction, a 7F quadruple lumen, thermistortipped, flow-directed catheter (Sorensen Research, Abbott, Salt Lake City, Utah), was advanced into the pulmonary artery via the right jugular vein. Nonpulsatile cardiopulmonary bypass was carried out using a roller pump and disposable bubble oxygenator. Flow rates were maintained at 2.2 L/min/m2 during cardiopulmonary bypass; mean arterial pressure was monitored and maintained between 60 and 80 mm Hg. Potassium cardioplegic arrest during the period of aortic clamping was used.
Lipids under the form of a 20 percent MCT/LCT physical mixture (Lipofundin MCT., B. Braun, Milan, Italy) were given at a rate of 1 ml/kg/h (3.3 mg/kg/min) for 2 h. Lipofundin MCT contains 100 g/L of MCT and 100 g/L of soybean LCT; 46 percent of fatty acids have a chain length of C6 to CIO, and 54 percent have a chain length of C16 to C18 (egg yolk phosphatides as emulsifiers).
Hemodynamic monitoring, arterial and mixed venous blood gas levels, and arterial oxygen saturation (SaO2) were obtained before the infusion, at 30, 60, 90, and 120 min during the infusion, and at 30, 60, and 120 min after the end of the infusion (washout period). At the same intervals, blood samples were taken for metabolic index measurement (triglycerides, FFA, acetoacetate, glucose, insulin, lactate).
Institutional protocols for the postoperative management of the patients studied were not altered during the period of the study; as a part of the routinely scheduled drugs regimen, mini-dose subcutaneous administration of heparin (5,000 IU three times a day) was given. Moreover, a 10 percent D-glucose infusion was started at arrival in the ICU at a rate of 33 ml/h (about 0.75 mg/kg/min). from baseline levels during the course of the study (Table 2) ; PaCO2 was constantly reduced throughout and after the end of lipid infusion; a statistically significant increase in oxygen consumption was found during lipid administration beginning from 30 min after the infusion was started, while oxygen delivery values remained stable; no adverse effects on intrapulmonary shunt fraction were documented during the study. During lipid infusion, the plasma concentration of tryglicerides and FFA significantly increased from baseline levels ( Table 3) ; peak value concentrations were reached between 90 and 120 min of infusion for both tryglicerides and FFA levels, with a rapid drop after the infusion was stopped. Peak values for acetoacetate were measured at the end of IVFE infusion. Both glucose and insulin levels increased significantly during lipid infusion, but while insulin returned to baseline values during the washout period, glucose remained elevated, with peak values at the end of the washout period. disease.' Following cardiac surgery, short-term, lowdose infusion of IVFE (1.1 mg/kg/min for 10 min to 2.35 mg/kg/min for 1 hr) had no effect on hemodynamic status or respiratory function,12'31 while higher doses (5.25 mg/kg/min for 2 hr) were associated with a decrease in cardiac output.12 In the latter study, a dose-response effect was shown for the decrease in cardiac output, and it was attributed to a myocardial depressive effect of IVFE. The possibility of a direct effect of IVFE administration on cardiac function cannot be excluded, since a negative inotropic effect with a parallel increase of peripheral vascular resistances has been shown after LCT infusion in an isovolumetric left heart canine preparation.11 Free fatty acids can significantly affect myocardial cell metabolism, and postulated mechanisms include inhibition of various aspects of membrane function, such as mitochondrial adenosine 5'-triphosphate-adenosine 5'-diphosphate translocase, the sodium/potassium pump, and phospholipid cycles. 32 The adverse effects of IVFE on cardiopulmonary function in human clinical beings are even more evident in the case of preexisting respiratory illness: in this condition, IVFE administration is in fact associated with decreased oxygenation, increased intrapulmonary shunt fraction, and increased mean pulmonary artery pressures and resistances;8'10 in particular, sepsis, and/or adult respiratory distress syndrome, are linked to more severe pulmonary vascular tone derangement and gas exchange alterations after IVFE administration. 8"10 No effects on either lung function or hemodynamic status were demonstrated in the group of patients we studied. Two factors could have accounted for this finding. First, since MCT-derived fatty acids are not eicosanoid precursors, less interference on both cardiac function and pulmonary vascular tone is to be expected as a result of the infusion of this component of the IVFE. Second, even though the total IVFE infusion rate was 3.3 mg/kg/min (equivalent to the mean infusion rate needed to give 500 ml of a 20 percent IVFE infusion in 8 h), the different fatty acid composition of the IVFE utilized-as compared with IVFE based solely on LCT-effectively reduced the infusion rate of the LCT component to about 1.65 mg/kg/min. The lipid infusion rate is thought to be an important determinant of the cardiopulmonary effects of IVFE, since it could elicit the predominant pathway of IVFE metabolism: it has been hypothesized that rapid infusion or bolus administration could lead to a net increase in vasoconstrictive eicosanoids (both prostaglandins and thromboxanes), as the enzymatic pathways for vasodilatory eicosanoids could be overwhelmed. 19-20'33 anisms which increase tissue oxygen extraction. This could be of particular interest in parenteral nutrition of patients with cardiac illness or reduced cardiac reserve, or both; artificial nutrition in these clinical conditions, in particular if malnutrition coexists, could be associated with an increased risk of refeeding syndrome, which encompasses many adverse effects on cardiovascular and respiratory systems. 42 Particular attention has been paid in our study to carbohydrate metabolism, since fatty acids are known to exert composite effects on glucose metabolism. While no clinically important alterations of plasma glucose levels have been demonstrated during and after MCT/LCT infusion in healthy subjects,43-45 hyperglycemia has been documented during MCT/ LCT administration in critically ill patients with trauma or sepsis, or both,46'47 and in acute renal failure.45 Also in our patients, the plasma glucose value increased during MCT/LCT infusion, reaching a steady state between 60 and 120 min of the infusion; thereafter, levels were further increased and remained high during the washout period. Plasma insulin levels, which were still high at baseline conditions, increased further during lipid administration but promptly returned to baseline values after the end of lipid administration.
MEASUREMENTS, ANALYTICAL PROCEDURES
Several mechanisms could contribute to hyperglycemia during the IVFE infusion; they are linked to an impairment of both oxidative and nonoxidative pathways of intracellular glucose disposal, as well as to an increased glucose production.
Elevations of plasma FFA due to triglyceride administration are known to inhibit glucose oxidation, as the consequence of substrate competition between glucose and FFA as oxidative fuels: as demonstrated by Randle et a148 in his original work, the addition of fatty acids to the perfusion medium of isolated rat hearts and hemidiaphragms was able to inhibit glucose transport, anaerobic utilization, and oxidation. While in healthy subjects in basal conditions, IVFE infusion induces hyperglycemia only if the compensatory insulin release (driven by a direct effect of FFA on beta-cell or mediated by the increasing glucose levels)49,50 is blocked by somatostatin infusion,51 the cycle noted by Randle et a148 has been demonstrated to be operative in man under several experimental and clinical conditions, which, like our experimental setting, are characterized to be highinsulin, high-glucose turnover states.52-58 Moreover, a constant glucose infusion was performed in our patients; as shown by Wolfe and colleagues,59 when the rate of glucose uptake is constant, increases in circulating FFA also may affect total glucose oxidation by suppressing glycogen oxidation.
The inhibition of glycogen synthesis, another mechanism involving nonoxidative glucose utilization, could have also contributed to the resistance to insulin-mediated glucose utilization associated with IVFE administration: glycogen synthesis is the most important nonoxidative glucose disposal pathway, and the inhibition of glucose storage observed during the experimental rise of FFA55 and in obesity60'61 appears to be a quantitatively important phenomenon.
Finally, IVFE administration could have determined hyperglycemia through increased hepatic production of glucose. Free fatty acids in fact stimulate gluconeogenesis from lactate, pyruvate, and alanine in in vitro conditions;62 multiple biochemical mechanisms are probably involved, which include acetylCoA generation from FFA, activation of pyruvate carboxylase, inhibition of pyruvate dehydrogenase and generation of adenosine 51-triphosphate and nicotinamide adenine dinucleotide (reduced form). An increased gluconeogenetic effect of FFA has been demonstrated in healthy subjects made moderately hyperglycemic56 or under pancreatic clamp with insulin and glucagon replacement at basal levels.51
Increased gluconeogenesis during lipid infusion also could be partially due to glycerol contained in IVFE;63'64 however, under this condition, glycerolinduced substrate effect explains only a variable percentage (40 to 70 percent) of the increased gluconeogenetic flux observed. In any case, the increase in plasma glucose levels demonstrated in our patients during MCT/LCT infusion should not cause clinical problems; it seems prudent, however, to monitor glucose levels during parenteral nutrition with glucose and IVFE.
In conclusion, the results obtained in our study suggest that the administration of an MCT-enriched IVFE at 3.3 mg/kg/min for 120 min is not associated with any adverse clinical or metabolic effects or with alterations of either hemodynamic status or lung function in heart surgery patients evaluated in the early postoperative phase following mitral valve replacement; thus, at least in this clinical condition, IVFE based on a physical mixture of MCT and LCT could represent an advantageous source of substrates.
